Patients with the fibrositis syndrome experience moderately severe musculoskeletal discomfort, mood changes associated with nonrestorative sleep, and tenderness to palpation at specific body sites. There is no characteristic abnormal laboratory finding in these patients to help identify the population. A report by Moldofsky and Warsh (Pain 1978; 5: 65-71) of low serum levels of free tryptophan in patients with severe fibrositis syndrome is intriguing but remains unexplained. Those data plus the observation by Hudson et al (Am J Psychiatry 1985; 142: 441-446; Biol Psychiatry 1984; 19: 1489-1493) that patients with fibrositis syndrome exhibit an increased prevalence of anxiety and depression suggest a number of possible avenues for further study. They include potential alterations in the homeostasis of catecholamines, corticosteroids, serotonin, aromatic amino acids, platelet membrane receptor levels, and the activity of platelet membrane monoamine oxidase. Among these possibilities, evidence is now available that suggests an increased production of catecholamines in fibrositis syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(86)90874-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibromyalgia syndrome-a bodily distress disorder/somatic symptom disorder?
Pain Rep
February 2025
Department Psychosomatic Medicine and Psychotherapy, Technical University Munich, Munich, Germany.
Introduction: The debate addressing the classification of chronic widespread pain as a physical disorder (fibromyalgia syndrome) [FMS] or a somatoform disorder according to psychiatric classification systems has continued for decades.
Objectives: The review aims to line out the new perspectives introduced by the 11th version of the International Classification of Diseases (ICD 11) of the World Health Organization (WHO).
Methods: Critical review of the classification criteria of fibromyalgia syndrome and bodily distress disorder in ICD 11.
The Relationship Between Fibromyalgianess and Clinical Features, Disease Activity in Patients With Systemic Lupus Erythematosus.
Musculoskeletal Care
March 2025
Department of Rheumatology, Karamanoğlu Mehmetbey University, Karaman, Turkey.
Introduction: Fibromyalgia (FM) is a chronic syndrome characterised by widespread pain, fatigue, and symptoms such as sleep disturbances, cognitive impairment, and mood disorders. FM prevalence is notably higher among systemic lupus erythematosus (SLE) patients compared with the general population, often leading to diagnostic challenges. Misinterpreting FM as SLE activity can result in overtreatment.
View Article and Find Full Text PDFExploring musculoskeletal disorders in end-stage kidney disease: a systematic review.
Med J Malaysia
January 2025
International Medical University, Department of Orthopaedics, Kuala Lumpur, Malaysia.
Introduction: This study focuses on the association between musculoskeletal disorders and chronic kidney disease (CKD), specifically end-stage kidney disease (ESKD). Its primary objective is to explore the spectrum of musculoskeletal disorders and to identify their prevalence rates and symptoms within diverse CKD subpopulations.
Materials And Methods: The screening process yielded 13 studies conducted in various countries and regions.
Small Fibre Pathology in Fibromyalgia: A review.
Pain Ther
January 2025
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, Clinical Sciences Centre, University Hospital Aintree, University of Liverpool and Liverpool University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK.
Fibromyalgia syndrome (FMS) presents a complex and challenging disorder in both the diagnosis and treatment, with emerging evidence suggesting a role of small fibre pathology (SFP) in its pathophysiology. The significance of the role of SFP in FMS remains unclear; however, recent evidence suggests degeneration and dysfunction of the peripheral nervous system, particularly small unmyelinated fibres, which may influence pathophysiology and underlying phenotype. Both skin biopsy and corneal confocal microscopy (CCM) have consistently demonstrated that ~ 50% of people with FMS have SFP.
View Article and Find Full Text PDFThe impact of community-based, non-pharmaceutical interventions on anxiety and depression in fibromyalgia: A systematic review and network meta-analysis.
J Psychiatr Res
January 2025
Beijing Hui-Long-Guan Hospital, Peking University, Beijing, 100096, China. Electronic address:
Background: Fibromyalgia syndrome (FMS) is often accompanied by anxiety and depression, seriously affecting the prognosis of patients. Active non-pharmacological therapies are the mainstay of treatment, but the optimal choice is still contentious.
Methods: We did a network meta-analysis(NMA) of RCTs and compared 7 community-based non-pharmacological interventions based on 29 studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!